Toggle light / dark theme

A groundbreaking study has provided experimental evidence suggesting a quantum basis for consciousness.

By demonstrating that drugs affecting microtubules within neurons delay the onset of unconsciousness caused by anesthetic gases, the study supports the quantum model over traditional classical physics theories. This quantum perspective could revolutionize our understanding of consciousness and its broader implications, potentially impacting the treatment of mental illnesses and our understanding of human connection to the universe.

Researchers have achieved a significant breakthrough in the synthesis of carbon nanotubes (CNTs) by developing a novel catalyst that allows for precise control over their atomic arrangement, known as chirality. This advancement paves the way for the creation of innovative semiconductor devices, addressing a challenge that has remained unresolved for over 30 years.

Using the European Southern Observatory’s Very Large Telescope (ESO’s VLT), astronomers have discovered an exoplanet orbiting Barnard’s star, the closest single star to our sun. On this newly discovered exoplanet, which has at least half the mass of Venus, a year lasts just over three Earth days. The team’s observations also hint at the existence of three more exoplanet candidates, in various orbits around the star.

Located just six light-years away, Barnard’s star is the second-closest stellar system—after Alpha Centauri’s three-star group—and the closest individual star to us. Owing to its proximity, it is a primary target in the search for Earth-like exoplanets. Despite a promising detection back in 2018, no planet orbiting Barnard’s star had been confirmed until now.

The discovery of this new exoplanet—announced in a paper published today in the journal Astronomy & Astrophysics—is the result of observations made over the last five years with ESO’s VLT, located at Paranal Observatory in Chile. “Even if it took a long time, we were always confident that we could find something,” says Jonay González Hernández, a researcher at the Instituto de Astrofísica de Canarias in Spain, and lead author of the paper.

Now AI Agents can do low-level work on your laptop. Paper pushers are on notice: the bots are coming for your job.


Anthropic just showed off a new trick — its AI assistant Claude can now take over your computer’s mouse and keyboard, clicking and typing its way through tasks while you sit and watch. All you have to do is tell it what you want done.

In a video, Developer Relations lead Alex Albert walks through a process where Claude performs multiple website development steps autonomously. The AI navigates Chrome, interacts with web interfaces, and even engages in a unique AI-to-AI interaction.

Protecting Human And Animal Health — Dr. Tristan Colonius, DVM — Chief Veterinary Officer & Deputy Director for Science Policy, Center for Veterinary Medicine (CVM), U.S. Food and Drug Administration (FDA)


Dr. Tristan Colonius, DVM is the Chief Veterinary Officer and Deputy Director for Science Policy at FDA’s Center for Veterinary Medicine (CVM — https://www.fda.gov/animal-veterinary).

Dr. Colonius previously worked in various positions at FDA, including as Deputy Chief of Staff to Commissioner Dr. Robert Califf and as an International Policy Analyst.

Mike Kelly is President & Chief Executive Officer of NervGen Pharma Corp. (https://nervgen.com/), a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease.

NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in an initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Mr. Kelly brings three decades of pharmaceutical experience playing instrumental roles in the creation, development and strengthening of several companies.

Most recently, Mr. Kelly served as President of US Operations for Adapt Pharma, Inc. from March 2016 to June 2019, and played a key leadership role in the development and commercialization of NARCAN (naloxone HCl) Nasal Spray in the US and Canada and in the eventual sale to Emergent BioSolutions for US$735 million.

This breakthrough could be used to make eco-friendly houses and structures in the near future.first appeared on The Cool Down.